Barinthus Biotherapeutics (BRNS) Capital Expenditures (2020 - 2025)
Historic Capital Expenditures for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q2 2025 value amounting to $32000.0.
- Barinthus Biotherapeutics' Capital Expenditures fell 8333.33% to $32000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $315000.0, marking a year-over-year decrease of 3167.03%. This contributed to the annual value of $892000.0 for FY2024, which is 8352.12% down from last year.
- According to the latest figures from Q2 2025, Barinthus Biotherapeutics' Capital Expenditures is $32000.0, which was down 8333.33% from $5000.0 recorded in Q1 2025.
- In the past 5 years, Barinthus Biotherapeutics' Capital Expenditures registered a high of $3.0 million during Q2 2023, and its lowest value of -$153000.0 during Q4 2023.
- In the last 5 years, Barinthus Biotherapeutics' Capital Expenditures had a median value of $293000.0 in 2024 and averaged $757000.0.
- Per our database at Business Quant, Barinthus Biotherapeutics' Capital Expenditures skyrocketed by 177968.75% in 2022 and then plummeted by 12610.92% in 2023.
- Quarter analysis of 5 years shows Barinthus Biotherapeutics' Capital Expenditures stood at $424000.0 in 2021, then skyrocketed by 38.21% to $586000.0 in 2022, then tumbled by 126.11% to -$153000.0 in 2023, then surged by 281.7% to $278000.0 in 2024, then tumbled by 88.49% to $32000.0 in 2025.
- Its Capital Expenditures stands at $32000.0 for Q2 2025, versus $5000.0 for Q1 2025 and $278000.0 for Q4 2024.